Skip to main content

Advertisement

SpringerLink
Log in

Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control

  • Original Research
  • Published:
Journal of Radiation Oncology

Abstract

Purpose/objectives

Stereotactic body radiation therapy for centrally located lung tumors has been associated with increased risk of toxicity. A current study aims to evaluate tumor control and toxicity in large cohort of centrally located lesions.

Methods

Central location was defined as tumors within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Tumors were biopsy proven or PET positive and included recurrent or primary non-small cell lung cancer (NSCLC). A dose was prescribed to a non-uniform planning target volume based on the internal tumor volume constructed from a 4D CT scan allowing for tumor motion. The treatment plans consisted of non-coplanar static aperture arcs and non-coplanar static fields. Treatments were delivered using 6MV X-rays with image guidance.

Results

At a median follow-up of 12.3 months, 107 total NSCLC tumors were retrospectively reviewed. A cohort consisted of primary (n = 57) and recurrent (n = 50) NSCLC tumors with subset of recurrent lesions including 27 hilar or mediastinal lymph nodes. Median and most frequent dose were 45 Gy in four fractions treated once weekly. Estimated 2-year Kaplan-Meier survival was 81.7%, with a significant survival advantage between primary and recurrent (p = 0.003). Eleven patients failed locally giving a 2-year actuarial local control rate of 80.7%, with control rates of 82.5 and 79.2% for primary and recurrent tumors, respectively (p = 0.828). Regional control at 2 years was not significantly different for primary (72.6%) and recurrent (62.7%). Analysis of toxicity revealed no grade 4 or 5 events. One grade 3 event was reported as pneumonitis. Grade 2 toxicity occurred in 10 patients, including dyspnea (1), chest wall pain (2), pneumonitis (4), rib fracture (1), and cough (2).

Conclusions

Moderate prescription dosing, treated once weekly, offers acceptable local control rates for centrally located tumors including recurrent mediastinal and hilar lymph nodes. Toxicity was minimal with the majority of patients experiencing no treatment-related adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

References

  1. Fakiris AJ, McGarry RC, Yiannoutsos CT et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75(3):677–682

    Article  PubMed  Google Scholar 

  2. Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070–1076

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Shirvani SM, Jiang J, Chang JY et al (2012) Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 84(5):1060–1070

    Article  PubMed  PubMed Central  Google Scholar 

  4. Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16(6):630–637

    Article  PubMed  PubMed Central  Google Scholar 

  5. Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24(30):4833–4839

    Article  PubMed  Google Scholar 

  6. Chang JY, Dong L, Liu H et al (2008) Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol 3(2):177–186

    Article  PubMed  Google Scholar 

  7. Chang JY, Li QQ, Xu QY et al (2014) Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a no fly zone. Int J Radiat Oncol Biol Phys 88(5):1120–1128

    Article  PubMed  Google Scholar 

  8. Senthi S, Haasbeek CJ, Slotman BJ, Senan S (2013) Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 106(3):276–282

    Article  PubMed  Google Scholar 

  9. Radiation therapy oncology group. Seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study+=0813. Updated 6/8/2015. Accessed 23 Sep 2015

  10. Bezjak A, Papiez L, Bradley J, Gore E, Gaspar L, Kong, MD, Feng-Ming Spring Phoenix (2012) Radiation therapy/NRG oncology group RTOG 0813 seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. Update

  11. Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, Onishi H, Shirato H (2009) Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 75(2):343–347

    Article  PubMed  Google Scholar 

  12. Corradetti MN, Haas AR, Rengan R (2012) Central-airway necrosis after stereotactic body-radiation therapy. N Engl J Med 366(24):2327–2329

    Article  PubMed  Google Scholar 

  13. US department of health and human services. National institutes of health. National cancer institute. Common terminology criteria for adverse events (CTCAE). (V4.03). http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Published 2010–6-14. Updated 2010. Accessed 18 Sep 2015

  14. Modh A, Rimner A, Williams E et al (2014) Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 90(5):1168–1176

    Article  PubMed  PubMed Central  Google Scholar 

  15. Davis JN, Medbery C, Sharma S et al (2015) Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch® patient registry. Radiat Oncol 10(1):113 015-0417-5

    Article  PubMed  PubMed Central  Google Scholar 

  16. Park H, Harder E, Mancini B et al (2015) Central versus peripheral tumor location: influence on survival, local control, and toxicity following stereotactic body radiotherapy for primary non-small-cell lung cancer. JThorac Oncol 10(5):832–837

    Article  Google Scholar 

  17. Schanne DH, Nestle U, Allgauer M et al (2015) Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol 191(2):125–132

    Article  PubMed  Google Scholar 

  18. Milano MT, Chen Y, Katz AW, Philip A, Schell MC, Okunieff P (2009) Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol 91(3):301–306

    Article  PubMed  Google Scholar 

  19. Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7):1623–1631

    Article  PubMed  Google Scholar 

  20. Oshiro Y, Aruga T, Tsuboi K et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186(5):274–279

    Article  PubMed  Google Scholar 

  21. Chang JY, Balter PA, Dong L et al (2008) Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(4):967–971

    Article  PubMed  PubMed Central  Google Scholar 

  22. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH (2012) Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 7(9):1394–1399

    Article  PubMed  Google Scholar 

  23. Nuyttens JJ, van der Voort van Zyp NC, Praag J et al (2012) Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol 102(3):383–387

    Article  PubMed  Google Scholar 

  24. Bral S, Gevaert T, Linthout N et al (2011) Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a phase II trial. Int J Radiat Oncol Biol Phys 80(5):1343–1349

    Article  PubMed  Google Scholar 

  25. Inoue T, Shiomi H, Oh RJ (2015) Stereotactic body radiotherapy for stage I lung cancer with chronic obstructive pulmonary disease: special reference to survival and radiation-induced pneumonitis. J Radiat Res 56(4):727–734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Radiation therapy oncology group. A randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study+=0915. Updated 2014. Accessed 9 Sep 2015

Download references

Author information

Authors and Affiliations

  1. Department of Radiosurgery, Riverside Regional Hospital, Newport News, VA, USA

    John Bowers, Nathan R. Bennion, Martin Richardson, Kelly Spencer & Ronald Kersh

  2. Department of Radiation Oncology, Baylor College of Medicine, One Baylor Plaza, MS BCM 711, Houston, TX, 77030, USA

    John Bowers

  3. Department of Radiation Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA

    James Larner & Ronald Kersh

Authors
  1. John Bowers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathan R. Bennion
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kelly Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James Larner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ronald Kersh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Bowers.

Ethics declarations

Funding

No funding was received for this study.

Conflict of interest

John Bowers declares he was previously employed by the Riverside Regional Medical Center. Nathan Bennion declares he was previously employed by the Riverside Regional Medical Center. Martin Richardson declares that he is a current employee of the Riverside Regional Medical Center. Kelly Spencer declares that he is a current employee of the Riverside Regional Medical Center. James Larner declares that he is a faculty member of the Department of Radiation Oncology, University of Virginia Cancer Center. Ronald Kersh declares that he is a faculty member of the Department of Radiation Oncology, University of Virginia Cancer Center, and employed by the Riverside Regional Medical Center.

Ethical approval

This study was granted approval by the IRB. This article does not contain any studies with human or animal subjects performed by any of the authors.

Informed consent

For this type of study, formal consent for study participation is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bowers, J., Bennion, N.R., Richardson, M. et al. Stereotactic body radiation therapy (SBRT) for centrally located primary and recurrent non-small cell lung cancer (NSCLC): analysis of toxicity and local control. J Radiat Oncol 6, 247–253 (2017). https://doi.org/10.1007/s13566-016-0289-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13566-016-0289-9

Keywords

Search

Navigation